LON:INDV

Indivior (INDV) Share Forecast, Price & News

GBX 1,626

-36.00 (-2.17%)

(As of 04:45 PM ET)

Compare

Today's Range: 1,621
▼
1,681
50-Day Range: 1,662
▼
1,885
52-Week Range: 1,330
▼
2,020

Volume: 228,021 shs
Average Volume: 391,503 shs
Market Capitalization: £2.24 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: GBX 2,460

Profile Analyst Ratings Chart Competitors Insider Trades Headlines

About Indivior (LON:INDV) Stock

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

INDV Price History

30 days | 90 days | 365 days | Advanced Chart

INDV Stock News Headlines

October 2, 2023 | finance.yahoo.com

Indivior PLC (INDV): Unveiling Its Market Value

September 26, 2023 | finance.yahoo.com

Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada

October 4, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

September 7, 2023 | finance.yahoo.com

Indivior PLC (INDV)'s True Worth: A Complete Analysis of Its Market Value

June 12, 2023 | finance.yahoo.com

The 7.5% return this week takes Indivior's (LON:INDV) shareholders three-year gains to 372%

June 12, 2023 | finance.yahoo.com

Indivior to Commence Trading on Nasdaq

June 7, 2023 | msn.com

Jefferies Reiterates Indivior (LSE:INDV) Buy Recommendation

June 5, 2023 | reuters.com

Indivior opioid settlement makes purer M&A case

October 4, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

June 3, 2023 | msn.com

US drugmaker Indivior to pay $102.5 million to settle Suboxone monopoly claims

June 2, 2023 | finanznachrichten.de

Indivior PLC: Indivior Reaches Agreement with States' Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation Claims

May 25, 2023 | uk.finance.yahoo.com

INDV.L - Indivior PLC

May 25, 2023 | finance.yahoo.com

Indivior To Participate In Upcoming Investor Conferences

May 23, 2023 | finance.yahoo.com

Indivior PLC Form 20-F Registration Statement for Additional US Listing Now Available; Trading on NASDAQ Expected to Commence on June 12th

May 22, 2023 | markets.businessinsider.com

FDA Approves Opiant's Nasal Spray 'Opvee' To Reverse Opioid Overdose

May 22, 2023 | reuters.com

US FDA approves Opiant's spray for reversing opioid-related overdoses

May 22, 2023 | finance.yahoo.com

Indivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl

April 27, 2023 | finance.yahoo.com

Indivior Announces Q1 2023 Financial Results

April 25, 2023 | finance.yahoo.com

Indivior To Participate In Bank of America Global Healthcare Conference 2023

March 2, 2023 | finance.yahoo.com

Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc.

February 16, 2023 | finance.yahoo.com

FY 2022 Financial Results Announced

February 6, 2023 | finance.yahoo.com

Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC

January 2, 2023 | finance.yahoo.com

Investing in Indivior (LON:INDV) three years ago would have delivered you a 861% gain

December 9, 2022 | finance.yahoo.com

Should You Be Excited About Indivior PLC's (LON:INDV) 73% Return On Equity?

December 7, 2022 | finance.yahoo.com

Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook

November 14, 2022 | finance.yahoo.com

Indivior To Acquire Opiant Pharmaceuticals

November 8, 2022 | finance.yahoo.com

Indivior Third Quarter 2022 Earnings: EPS: US$0.29 (vs US$0.18 in 3Q 2021)

See More Headlines

Receive INDV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Drug Manufacturers—Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:INDV
CUSIP: N/A
CIK: N/A
Web: indivior.com
Phone: +44-1753-217800
Fax: N/A
Employees: 1,000
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: GBX 2,460
High Stock Price Forecast: GBX 2,700
Low Stock Price Forecast: GBX 2,330
Forecasted Upside/Downside: +48.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): GBX (0.33)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 1,567.92
P/E Growth: -5.57
Net Income: £-59,000,000.00
Net Margins: -5.89%
Pretax Margin: N/A
Return on Equity: -34.01%
Return on Assets: 8.62%

Debt

Debt-to-Equity Ratio: 240.17
Current Ratio: 1.13
Quick Ratio: 1.52

Sales & Book Value

Annual Sales: £1 billion
Price / Sales: 2.29
Cash Flow: GBX 620.13 per share
Price / Cash Flow: 2.68
Book Value: GBX 85 per share
Price / Book: 19.55

Miscellaneous

Outstanding Shares: 137,940,000
Free Float: N/A
Market Cap: £2.29 billion
Optionable: Not Optionable
Beta: N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Mark Crossley
CEO & Exec. Director

Mr. Ryan Preblick
CFO & Exec. Director

Dr. Christian Heidbreder
Chief Scientific Officer

Mr. Jason Thompson
VP of Investor Relations

Ms. Cynthia Cetani
Chief Integrity & Compliance Officer

Mr. Jeffrey W. Burris (Age 51)
Chief Legal Officer

Mr. Jon Fogle
Chief HR Officer

Mr. Richard Simkin
Chief Commercial Officer

Mr. Hillel West
Chief Manufacturing & Supply Officer

Ms. Nina DeLorenzo
Chief Global Impact Officer

Key Competitors

View All Competitors

Insiders

Mark Stejbach
Bought 1,400 shares on 3/6/2023
Total: £2.10 M ($1,502.00/share)

View All Insider Transactions

INDV Stock - Frequently Asked Questions

Should I buy or sell Indivior stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INDV shares.
View INDV analyst ratings or view top-rated stocks.
What is Indivior's stock price forecast for 2023?: 2 Wall Street analysts have issued twelve-month price targets for Indivior's shares. Their INDV share price forecasts range from GBX 2,330 to GBX 2,700. On average, they predict the company's stock price to reach GBX 2,460 in the next year. This suggests a possible upside of 48.0% from the stock's current price.
View analysts price targets for INDV or view top-rated stocks among Wall Street analysts.
How have INDV shares performed in 2023?: Indivior's stock was trading at GBX 1,852 at the start of the year. Since then, INDV shares have decreased by 10.3% and is now trading at GBX 1,662.
View the best growth stocks for 2023 here.
What other stocks do shareholders of Indivior own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Bigblu Broadband (BBB), Futura Medical (FUM), Directa Plus (DCTA), Lakehouse (LAKE), Aquila Services Group (AQSG), Benchmark (BMK), Bodycote (BOY), CityFibre Infrastructure (CITY), Deltex Medical Group (DEMG) and Kingfisher (KGF).

What is Indivior's stock symbol?: Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV."
How do I buy shares of Indivior?: Shares of INDV stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Indivior's stock price today?: One share of INDV stock can currently be purchased for approximately GBX 1,662.
How much money does Indivior make?: Indivior (LON:INDV) has a market capitalization of £2.29 billion and generates £1 billion in revenue each year. The specialty pharmaceutical company earns £-59,000,000.00 in net income (profit) each year or GBX (0.33) on an earnings per share basis.
How many employees does Indivior have?: The company employs 1,000 workers across the globe.
How can I contact Indivior?: Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The official website for the company is indivior.com. The specialty pharmaceutical company can be reached via phone at +44-1753-217800.

This page (LON:INDV) was last updated on 10/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial